Journal of Cardiovascular Pharmacology and Therapeutics · 2002 · 22 citations · 8 references
MedicineCardiologyHematologyCardiothoracic SurgeryInterventional CardiologyTransfusion MedicineAcute Coronary Syndrome InterventionPlatelet DisordersPlatelet PhysiologyPlatelet TransfusionThrombosisPercutaneous Coronary Intervention CarePlatelet Transfusion In SurgeryPlatelet Transfusion In ThrombocytopeniaPlatelet Transfusion ReactionsPlatelet Transfusion TherapyTherapeutic Platelet Transfusion
A case of a 65-year-old woman presenting with delayed profound thrombocytopenia 7 days after the use of abciximab (ReoPro) in the setting of percutaneous coronary intervention is described. The patient had normal platelet counts for the first 24 hours after the use of abciximab (ReoPro). She presented with petechiae and profound thrombocytopenia 1 week later. The patient was treated successfully with a platelet transfusion and recovered uneventfully. Profound thrombocytopenia occurs acutely within the first few hours after abciximab (ReoPro) use, so this case was unique in that the profound thrombocytopenia presented 1 week after use of abciximab (ReoPro).
8
Acute Profound Thrombocytopenia After c7E3 Fab (Abciximab) Therapy
Scott D. Berkowitz, Robert A. Harrington, Michele M. Rund et al. · Circulation · 1997 · 234 citations
Medicine, Cardiology, Hematology +17
James E. Tcheng, Dean J. Kereiakes, A. Michael Lincoff et al. · Circulation · 2001 · 141 citations · Full text
Dean J. Kereiakes, Scott D. Berkowitz, A. Michael Lincoff et al. · American Heart Journal · 2000 · 85 citations
Medicine, Cardiology, Hematology +16